Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

NCT00772005
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Little Rock, Arkansas • Anaheim, California • Escondido, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 15, 2026, 4:58 PM EDT
Not listed Phase 4 Interventional

Adjunctive Vortioxetine in Schizophrenia

NCT02357797
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms
Interventions
Vortioxetine, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Lauderdale Lakes, Florida • Grand Rapids, Michigan • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

NCT00793780
View directory record Official record
Conditions
Obesity, Schizophrenia, Schizoaffective Disorder
Interventions
Naltrexone 25mg, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Brain Stimulation and Cognitive Training

NCT03338673
View directory record Official record
Conditions
Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
Interventions
tDCS, BrainHQ
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 4 Interventional

Study of Vitamin D in the Severely Mentally Ill

NCT01169142
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Bronx Psychiatric Center
Government
Eligibility
19 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 1 Interventional

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

NCT06315283
View directory record Official record
Conditions
Schizophrenia
Interventions
TV-44749, Oral olanzapine
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Los Alamitos, California • Torrance, California • Hollywood, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 15, 2026, 4:58 PM EDT
Terminated Phase 2Phase 3 Interventional

A Long-Term, Open-Label, Study on Schizophrenia

NCT01129674
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

NCT02417142
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

NCT00338949
View directory record Official record
Conditions
Schizophrenia, Metabolic Syndrome X, Insulin Resistance
Interventions
Switch, Control
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 4 Interventional

The Effects of Risperidone and Olanzapine on Thinking

NCT00108368
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Risperidone, Olanzapine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

NCT02161718
View directory record Official record
Conditions
Schizophrenia, Alcohol Use Disorder
Interventions
Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
58
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Transcranial Magnetic Stimulation for "Voices"

NCT00308997
View directory record Official record
Conditions
Schizophrenia, Hallucinations
Interventions
1-hertz Repetitive Transcranial Magnetic Stimulation, Active 1-Hertz Repetitive transcranial magnetic stimulation
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 4 Interventional

Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility

NCT00308360
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, divalproex
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2006 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

NCT04187560
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 1 Interventional Results available

Weight Management Program for Patients With First Episode Psychosis

NCT05207982
View directory record Official record
Conditions
Diet, Healthy, Psychotic Disorders
Interventions
Family Based weight management program
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
14 Years to 26 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 3 Interventional

Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.

NCT00380224
View directory record Official record
Conditions
Schizophrenia
Interventions
bifeprunox, olanzapine
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
67
States / cities
Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 55 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 15, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional

Study Evaluating Bifeprunox in Patients With Schizophrenia.

NCT00366327
View directory record Official record
Conditions
Schizophrenia
Interventions
Bifeprunox
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 66 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
82
States / cities
Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 66 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole

NCT00205660
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Stayers, Switchers
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

NCT01050582
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
Interventions
Risperidone, Other atypical antipsychotic drugs
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
8 Years to 16 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Accelerated DMN-Targeted cTBS to Modulate DMN Connectivity

NCT07155096
View directory record Official record
Conditions
Schizophrenia
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

Huperzine for Cognitive and Functional Impairment in Schizophrenia

NCT00963846
View directory record Official record
Conditions
Schizophrenia
Interventions
placebo, huperzine 0.2 mg BID, huperzine 0.4 mg BID, huperzine 0.8 mg BID
Drug
Lead sponsor
Biomedisyn Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01490086
View directory record Official record
Conditions
Acute Schizophrenia, Schizoaffective Disorder
Interventions
RP5063, placebo, aripiprazole
Drug
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 15, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)

NCT00119574
View directory record Official record
Conditions
Schizophrenia Disorders, Chronic Illness, Schizoaffective Disorder, Weight Gain
Interventions
Collaborative Chronic Illness Model
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 15, 2026, 4:58 PM EDT